Ovid Therapeutics Inc. has provided an update on its strategic focus and ongoing developments in their corporate presentation. The company is concentrating on foundational biological targets related to neuronal hyperexcitability, with an emphasis on precision small molecules and differentiated mechanisms of action. Ovid reports a cash balance of $43 million, anticipated to support operations into the second half of 2026. The company highlighted its differentiated pipeline, including OV329, a next-generation GABA-aminotransferase inhibitor aimed at drug-resistant epilepsies. The Phase 1 safety and biomarker results for OV329 are expected in Q3 2025, with Phase 2 initiation planned for Q1 2026. Other pipeline developments include OV350, a KCC2 direct activator, and OV4041 for generalized anxiety disorder or Rett syndrome. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。